BioPharma Dive3d
Sarepta rebuilds drug pipeline with Arrowhead deal
A broad licensing and research alliance will hand Sarepta four clinical-stage candidates, while Arrowhead receives $500 ...
BioPharma Dive3d
Kronos, Idorsia plan layoffs; PTC shelves ALS drug
Kronos is cutting 83% of its workforce, while Idorsia is considering eliminating as many as 270 jobs. Elsewhere, PTC ...
BioPharma Dive3d
How Intra-Cellular surprised Wall Street by breaking character
The biotechnology company, which sees itself as "pretty conservative," recently put out an ambitious long-term revenue ...
BioPharma Dive3d
Merz Therapeutics and S3 Connected Health Pioneer New Digital Health Solution, iFlexo, for People Living with Post-Stroke Spasticity
Dublin/Frankfurt, 27 November, 2024 - Merz Therapeutics launches iFlexo, a personalized digital solution aimed at enhancing ...
BioPharma Dive4d
Amgen obesity drug cuts weight in study, but results miss Wall Street’s high mark
Shares in Amgen fell by double digits Tuesday on results for the company’s MariTide shot, which is viewed as a potential ...
BioPharma Dive4d
Roche’s TIGIT-targeting drug for cancer fails its biggest test
Long-awaited results released Tuesday showed adding tiragolumab to Roche's immunotherapy Tecentriq did not extend survival in ...
BioPharma Dive4d
Roche to buy cell therapy developer Poseida for $1B
The deal suggests Roche sees substantial promise in Poseida’s technology, as the offer is 215% above the biotech’s closing ...
BioPharma Dive4d
Patsnap Launches Hiro Life Sciences – Revolutionizing Drug Research with Generative AI
Patsnap, a global leader in innovation and pharma intelligence, announced the launch of Hiro Life Sciences (Hiro LS), a groundbreaking AI assistant poised to redefine biopharmaceutical research and ...